Skip to main navigation
Skip to search
Skip to main content
Bar-Ilan University Home
Help & FAQ
Home
Researchers
Organisations
Research output
Prizes
Student theses
Courses
Activities
Projects
Press/Media
Datasets
Equipment
Search by expertise, name or affiliation
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
EXAMINE Investigators
Bar-Ilan University - Azrieli Faculty of Medicine
University of Connecticut
Brigham and Women’s Hospital
University of Sheffield
Cleveland Clinic Foundation
Park Nicollet Health Services
The University of Chicago
Takeda Development Center Americas, Inc.
Harvard University
University of Tennessee Health Science Center
Université de Lorraine
Research output
:
Contribution to journal
›
Article
›
peer-review
2277
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Alogliptin after acute coronary syndrome in patients with type 2 diabetes'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Acute Coronary Syndrome
100%
Type 2 Diabetic Patients
100%
Alogliptin
100%
Placebo
85%
Hazard Ratio
28%
Antihyperglycemic
28%
Dipeptidyl peptidase-4 (DPP-4)
28%
Hospitalization
14%
Hypoglycemia
14%
Non-inferiority Trial
14%
Safety Profile
14%
Nonfatal Myocardial Infarction
14%
Cardiovascular Risk
14%
Stable Angina
14%
Cardiovascular Outcomes
14%
Major Adverse Cardiovascular Events
14%
Nonfatal Stroke
14%
Non-inferiority
14%
Regulatory Agencies
14%
Drug Therapy
14%
Pancreatitis
14%
Comprehensive Evaluation
14%
Upper Boundary
14%
Cardiovascular Safety
14%
Acute Myocardial Infarction
14%
New Inhibitors
14%
Antidiabetic Therapy
14%
Noninferiority Margin
14%
Dialysis Initiation
14%
New Antidiabetic Drugs
14%
Glycated Hemoglobin Levels
14%
Repeated Confidence Intervals
14%
Cardiovascular Drugs
14%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Acute Coronary Syndrome
100%
Alogliptin
100%
Placebo
85%
Cardiovascular Disease
14%
Pharmacotherapy
14%
Malignant Neoplasm
14%
Heart Infarction
14%
Antidiabetic Agent
14%
Cardiovascular Risk
14%
Glycosylated Hemoglobin
14%
Unstable Angina Pectoris
14%
Pancreatitis
14%
Acute Heart Infarction
14%
Cardiovascular Agent
14%
Dipeptidyl Peptidase IV Inhibitor
14%
Dipeptidyl Peptidase IV
14%
Noninferiority Trial
14%
Hypoglycemia
14%